Loading
A phase 3 trial of Docetaxel in triple-negative breast cancer, run by Jina Pharmaceuticals Inc., now recruiting.
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients is a phase 3 interventional study registered as NCT03671044 by Jina Pharmaceuticals Inc., with 657 participants planned, started 2018-07-10 and due to reach its primary completion in 2025-05-31. Interventions recorded: Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2) and Taxotere® (100 mg/m2).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.